Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study.
JSON
Santosa A, Franzén S, Nåtman J, Wettermark B, Parmryd I, Nyberg F
Sci Rep 12 (1) 12047 [2022-07-14; online 2022-07-14]
The impact of statins on COVID-19 remains unclear. This study aims to investigate whether statin exposure assessed both in the population and in well-defined cohorts of COVID-19 patients may affect the risk and severity of COVID-19 using nationwide Swedish population-based register data. A population ≥ 40 years was selected by age/sex-stratified random sampling from the Swedish population on 1 Jan 2020. COVID-19 outcomes were identified from the SmiNet database, the National Patient Register and/or Cause-of-Death Register and linked with the National Prescribed Drug Register and sociodemographic registers. Statin exposure was defined as any statin prescriptions in the year before index date. In Cox regressions, confounding was addressed using propensity score ATT (Average Treatment effect in the Treated) weighting. Of 572,695 individuals in the overall cohort, 22.3% had prior statin treatment. After ATT weighting, protective effects were observed among statin user for hospitalization and COVID-19 death in the overall cohort and onset cohort. In the hospitalized cohort, statin use was only associated with lower risk for death (HR = 0.86, 95% CI 0.79-0.95), but not ICU admission. Statin-treated individuals appear to have lower COVID-19 mortality than nonusers, whether assessed in the general population, from COVID-19 onset or from hospitalization.
Topics: Register-based research
PubMed 35835835
DOI 10.1038/s41598-022-16357-2
Crossref 10.1038/s41598-022-16357-2
pii: 10.1038/s41598-022-16357-2
pmc: PMC9282150